Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that ...
Zacks Investment Research on MSN
Can Keros Therapeutics Rinvatercept stand out in the DMD market?
Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients ...
Trent, is supporting Muscular Dystrophy UK, the leading charity for more than 110,000 children and adults in the UK ...
Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.
NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today ...
We lead busy lives, and between school, work or spending time with family, it can be tricky to make time for working out, especially when first establishing a regular exercise routine. But keep this ...
CINCINNATI (WKRC) - A medical exercise program at the TriHealth Fitness and Health Pavilion is offering a tailored approach to fitness, helping participants like Lori Ledermeier and Kim Rioux meet ...
Before market open, Dyne announced that its zeleciment rostudirsen -- a treatment targeting the genetic disorder Duchenne muscular dystrophy (DMD) -- had achieved its primary endpoint in a phase 1/2 ...
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients. By Christina Jewett The Food and Drug Administration said on ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results